et the query remains on tips on how to predict these complications. It is relevant to consider prophylactic measures for avoiding hypercoagulability. Progressive diffuse abdominal discomfort with no important alterations on coagulation profile or other threat aspects should really raise the awareness for mesenteric thrombosis. Truly, couple of situations of intestinal thrombosis exist within the literature thinking of our patient certainly one of the initial cases of subacute mesenteric venous thrombosis within a non-severe COVID-19 patient. Extra case reports and descriptive information are needed in the literature to boost the index of suspicion for these kinds of complications.studies concluding that there’s no difference in collateral formation, recanalization and mortality, regardless of whether anticoagulation had been prescribed or not. These findings emphasize the predominant part of inflammation, increasing uncertainty of risk/benefit ratio of anticoagulation. When portal and superior mesenteric veins are affected, anticoagulation seems a reasonable attitude, thinking of the threat of hepatic decompensation and bowel ischemia. Much more studies are necessary to consolidate this evidence and to establish well-defined recommendations in other scenarios (e.g., isolated thrombosis of splenic vein, as in this case).V T E D I AG N O S I S PB1175|Detection of Right Ventricular Dysfunction in Acute Pulmonary Embolism by CT Scan: A Systematic Review and Metaanalysis N. Chornenki1; K. Poorzargar2; M. Shanjer2; L. Mbuagbaw2;PB1174|Does Anticoagulation Affect Outcome of Splenic Vein Thrombosis in Acute Pancreatitis L. Vieira; S. Lopes; R. Pombal; R. Neto; A. Magalh s; M. Figueiredo Immunohemotherapy Service, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal Background: Splanchnic venous thrombosis (SVT) is really a wellestablished complication of acute pancreatitis (AP) and might have an Estrogen receptor Agonist drug effect on splenic, portal and superior mesenteric veins, either isolated or in mixture. Its pathogenesis is closely linked to inflammation, top to cellular infiltration, formation of pancreatic/peripancreatic collections that contribute to venous stasis and systemic activation of haemostasis. Aims: Description of a case of SVT AP-associated. Procedures: Collection of clinical information in SCl ico application. Results: A 47-year-old female patient, with antecedents of previous AP secondary to hypertriglyceridemia, was admitted to emergency department with pain in upper quadrants of abdomen, radiating towards the back, with nausea and vomiting, more than the previous handful of hours. Via clinical, analytical and imaging evaluation, the diagnosis of AP secondary to hypertriglyceridemia was established. The patient was hospitalized and, 4 days later, due to clinical worsening, a computed tomography (CT) was performed, revealing splenic vein thrombosis and pancreatic necrosis. Enoxaparin in therapeutic dose was initiated. The patient remained hospitalized for 18 days and enoxaparin was replaced by rivaroxaban 20mg as soon as daily at discharge. Three months later, CT showed persistence of thrombosis, with perigastric/perisplenic collateral circulation. Contemplating this in depth collateral circulation, comprehensive recanalization was no longer expected. Anticoagulation was maintained for any total period of six months. Conclusions: Management of thrombosis in AP remains challenging. There’s no consensus on anticoagulation within this setting, with someM. Crowther2; A. CDK4 Inhibitor site Delluc3; D. SiegalQueens University, Kingston, Canada; 2McMaster University,Hamilton, Cana
